Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)

Market Cap	6.83B +8.3%
Revenue (ttm)	1.17B -25.0%
Net Income	345.55M -0.9%
EPS	0.33 -0.9%
Shares Out	1.05B
PE Ratio	19.76
Forward PE	n/a
Dividend	0.06 (0.92%)
Ex-Dividend Date	Nov 27, 2025

Volume	24,224,817
Average Volume	32,458,583
Open	6.33
Previous Close	6.51
Day's Range	6.33 - 6.54
52-Week Range	5.36 - 7.03
Beta	0.32
RSI	58.58
Earnings Date	Apr 22, 2026

About SHE:300039

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,225
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300039

Financial Performance

In 2024, SHE:300039's revenue was 1.47 billion, a decrease of -7.57% compared to the previous year's 1.59 billion. Earnings were 375.58 million, an increase of 14.55%.